Expanding the public health benefits of syringe exchange programs

Canadian Journal of Psychiatry

Volumn 53, Issue 8, 2008, Pages 487-495

  Kidorf, Michael ^a,b   King, Van L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Harm reduction; Injection drug use; Substance abuse treatment; Syringe exchange

Indexed keywords

HARM REDUCTION; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HELP SEEKING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MEDLINE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; REVIEW; SUBSTANCE ABUSE; SYRINGE; TREATMENT REFUSAL; VIRUS TRANSMISSION;

EID: 50049123582     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370805300803     Document Type: Review

References (51)

1. Vlahov D, Des Jarlais DC, Goosby E, et al. Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy. Am J Epidemiol. 2001;154(12):S70-S77.
2. Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med. 2000;51(12):1771-1782.
3. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329-1341.
4. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7):777-813.
5. Des Jarlais DC, Braine N, Yi H, et al. Residual injection risk behavior, HIV injection, and the evaluation of syringe exchange programs. AIDS Educ Prev. 2007;19(2):111-123.
6. Wood E, Lloyd-Smith E, Li K, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med. 2007;120(2):172-179.
7. Fisher DG, Fenaughty AM, Cagle HH, et al. Needle exchange and injection drug use frequency: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;33(2):199-205.
8. Heinzerling KG, Kral AH, Flynn NM, et al. Unmet needs for recommended preventive health services among clients of California syringe exchange programs: implications for quality improvement. Drug Alcohol Depend. 2006;81(2):167-178.
9. Strathdee SA, Ricketts EP, Huettner S, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225-232.
10. Brooner R, Kidorf M, King V, et al. Drug abuse treatment success among needle exchange participants. Public Health Rep. 1998;113(Suppl 1):129-139.
11. Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146(12):994-1002.
12. Hahn JA, Vranizan KM, Moss AR. Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):157-164.
13. Kidorf M, Disney ER, King VL, et al. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74(2):115-122.
14. Disney E, Kidorf M, Kolodner K, et al. Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants. J Nerv Ment Dis. 2006;194(8):577-583.
15. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.
16. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17-31.
17. Tempalski B, Flom PL, Friedman SR, et al. Social and political factors predicting the presence of syringe exchange programs in 96 US metropolitan areas. Am J Public Health. 2007;97(3):437-447.
18. Bluthenthal RN, Kral A, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605-611.
19. Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348:987-991.
20. Gibson DR, Brand RS, Anderson K, et al. Two to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr. 2002;31(2):237-242.
21. Amundsen EJ. Measuring effectiveness of needle and syringe exchange programmes for prevention of HIV among injecting drug users. Addiction. 2006;101(7):911-912.
22. Cao W, Treloar C. Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug Alcohol Rev. 2006;25(5):439-444.
23. Des Jarlais DC, Braine N, Friedmann P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav. 2007; [Epub ahead of print].
24. Van Den Berg C, Smit C, Brussel GV, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102(9):1454-1462.
25. Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abuse Treat. 1998;15(3):183-191.
26. Kidorf M, Disney E, King V, et al. Challenges in motivating treatment enrollment in community syringe exchange participants. J Urban Health. 2005;82(3):456-467.
27. Riley ED, Safaeian M, Strathdee SA, et al. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse. 2002;37(14):1869-1886.
28. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 1996;42(1):11-20.
29. Jackson JF, Rotkiewicz LG, Quinones MA, et al. A coupon program-drug treatment and AIDS education. Int J Addict. 1989;24(11):1035-1051.
30. Bigelow GE, Brooner RK, Silverman K. Competing motivations: drug reinforcement vs non-drug reinforcement. J Psychopharmacol. 1998;12(1):8-14.
31. Metzger DS, Navaline H. HIV prevention among injection drug users: the need for integrated models. J Urban Health. 2003;80(4 Suppl 3):59-66.
32. Brooner RK, Kidorf MS, King VL, et al. Behavioral contingencies improve counseling attendance in an adaptive treatment model. J Subst Abuse Treat. 2004;27(3):223-232.
33. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269(15):1953-1959.
34. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York (NY): The Guilford Press; 2002.
35. King VK, Kidorf M, Peirce J, et al. Results from a controlled trial of a motivational intervention for improving treatment enrollment among needle exchange participants. Poster presented at: College on Problems of Drug Dependence. 2007 June; Quebec City (Quebec).
36. Booth RE, Kwiatkowski C, Iguchi MY, et al. Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep. 1998;113(Suppl 1):116-128.
37. Robles RR, Reyes JC, Colon HM, et al. Effects of combined counseling and case management to reduce HIV risk behaviors among Hispanic drug injectors in Puerto Rico: a randomized controlled study. J Subst Abuse Treat. 2004;27(2):145-152.
38. Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol. 2003;71(5):843-861.
39. Higgins ST, Silverman K, editors. Motivating behavior change among illicit-drug abusers: research on contingency management interventions. Washington (DC): American Psychological Association; 1999.
40. Stitzer ML, Petry N, Silverman K. Contingency management therapies. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore (MD): Johns Hopkins University Press; 2006. p 151-177.
41. Kwiatkowski CF, Booth RE, Lloyd LV. The effects of offering free treatment to street-recruited opioid injectors. Addiction. 2000;95(5):697-704.
42. Sorensen JL, Costantini MF, Wall TL, et al. Coupons attract high-risk untreated heroin users into detoxification. Drug Alcohol Depend. 1993;31(3):247-252.
43. Kuo I, Brady J, Butler C, et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program; experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat. 2003;24(1):67-74.
44. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102-109.
45. Yancovitz SR, Des Jarlais DC, Peyser NP. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185-1191.
46. Krook AL, Brors O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533-542.
47. Kidorf M, King VL, Brooner RK. Counseling and psychosocial services. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore (MD): Johns Hopkins University Press; 2006. p 119-150.
48. Marlowe DB, Merikle EP, Kirby KC, et al. Multidimensional assessment of perceived treatment-entry pressures among substance abusers. Psychol Addict Behav. 2001;15(2):97-108.
49. Friedmann PD, Lemon SC, Stein MD. Transportation and retention in outpatient drug abuse treatment programs. J Subst Abuse Treat. 2001;21(2):97-103.
50. McNeely J, Arnsten JH, Gourevitch MN. Improving access to sterile syringes and safe syringe disposal for injection drug users in methadone maintenance treatment. J Subst Abuse Treat. 2006;31(1):51-57.
51. Greenfield L, Brady JV, Besteman KJ, et al. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996;(42):125-131.